Enzalutamide treatment sensitivity recovery effect of docetaxel treatment after relapse of enzalutamide treatment for castration-resistant prostate cancer patients

Enzalutamide treatment sensitivity recovery effect of docetaxel treatment after relapse of enzalutamide treatment for castration-resistant prostate cancer patients - ESRED study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019325

Enrollment

Registered

2015-11-01

Start date

2015-11-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Castration-resistant prostate cancer

Interventions

Enzaltamide 160mg per day by oral after docetaxel (at a dose of 70 mg/m2 every three or four weeks for six cycles)

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. 20 years old or more 2. Diagnosed as prostate cancer by histological examination 3. Testosterone < 50ng/dL 4. Progression on the image or PSA relapse 5. 2 months or more has passed from operation for metastasis or radiation therapy. 6. PS of ECOG; 0-2 7. Liver and renal function are adequate 8. Life expectancy is more than 6 months

Exclusion criteria

Exclusion criteria: 1. Patients treated by chemotherapy 2. Patients judged to be inappropriate to perform this study by investigator

Design outcomes

Primary

Measure	Time frame
Biochemical-free survival rate (Prostate specific antigen progression free survival rate (PSA-PFS)) after enzalutamide retreatment	—

Countries

Japan

Contacts

Public ContactTsutomu Nishiyama

Uonuma Institute of Community Medicine Niigata University Medical and Dental Hospital Department of Urology

nisiyama@med.niigata-u.ac.jp025-777-3200

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026